{"organizations": [], "uuid": "93e22b33830492a548178f664eb29bd0b147ebd0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/UKHealthNews/", "section_title": "Reuters: Health News", "url": "https://uk.reuters.com/article/us-axovant-sciences-study/axovant-to-scrap-intepirdine-program-after-dementia-trial-fails-idUKKBN1EX14X", "country": "US", "domain_rank": 408, "title": "Axovant to scrap intepirdine program after dementia trial fails", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T14:30:00.000+02:00", "replies_count": 0, "uuid": "93e22b33830492a548178f664eb29bd0b147ebd0"}, "author": "", "url": "https://uk.reuters.com/article/us-axovant-sciences-study/axovant-to-scrap-intepirdine-program-after-dementia-trial-fails-idUKKBN1EX14X", "ord_in_thread": 0, "title": "Axovant to scrap intepirdine program after dementia trial fails", "locations": [], "entities": {"persons": [{"name": "reut", "sentiment": "negative"}, {"name": "axovant", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}, {"name": "savio d'souza", "sentiment": "none"}, {"name": "lewy", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "axovant sciences ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 33 PM / Updated 21 minutes ago Axovant to scrap intepirdine program after dementia trial fails Reuters Staff 1 Min Read \n(Reuters) - Axovant Sciences Ltd said on Monday it would discontinue its intepirdine program after the experimental treatment failed in a mid-stage study on patients suffering from a type of dementia. \nNeither of the two doses of intepirdine given to patients with dementia with Lewy bodies resulted in improving their motor function, compared with patients given a placebo, Axovant said. \nIn September, Axovant stopped testing the drug on patients suffering from Alzheimerâ€™s after a late-stage trial failure. Reporting by Tamara Mathias in Bengaluru; Editing by Savio D'Souza", "external_links": [], "published": "2018-01-08T14:30:00.000+02:00", "crawled": "2018-01-08T14:59:20.013+02:00", "highlightTitle": ""}